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‘‘Triple-negative’’ breast cancers are aggressive malignancies that respond poorly to treatments.
Now Sun et al. (2011) find that the activity of the protein tyrosine phosphatase PTPN12 is lost
in a large percentage of this breast cancer subtype, offering molecular drivers and possible thera-
peutic targets for this heterogeneous and intractable cancer.The molecular characterization of breast
cancer subtypes has lead to significant
progress in treating this common disease.
Tumors that express the estrogen recep-
tor (ER) or progesterone receptor (PR)
respond well to ER antagonists or aroma-
tase inhibitors (which block estrogen
synthesis), whereasHER2-positive tumors
are effectively treated with a HER2-block-
ing antibody (Trastuzumab) or a HER2
kinase inhibitor (Trikerb).
However, 15%–20% of breast cancers
fall through the cracks of this classification
scheme. Called ‘‘triple-negative’’ breast
cancers, these cells lack detectable
expression of the three key molecular
signatures: ER, PR, and overexpressed
HER2. Triple-negative breast cancers
have theworst prognosis among all breast
cancers and the fewest treatment options.
Because these cancers are defined by
what they lack, no common molecular
‘‘drivers’’ are available for developing
targeted therapies. Moreover, triple-
negative breast cancers are a highly
heterogeneous group, and it has been
difficult to identify common mutations
underlying the disease. In this issue of
Cell, Sun et al. (2011) uncover a new
molecular feature common to a large frac-
tion of triple-negative breast cancers: the
loss of the protein tyrosine phosphatase
PTPN12 (also known as PTP-PEST).
Sun et al. begin by performing a loss-
of-function screen for human kinases
and phosphatases that regulate
anchorage-independent growth in human
breast epithelial cells. The top hit was
PTPN12. They then show that loss of
PTPN12 expression enables these cells
to grow in the absence of extracellular638 Cell 144, March 4, 2011 ª2011 Elsevier Imatrix and also leads to their hyperprolif-
eration in a three-dimensional culture
model that recapitulates structures of
the mammary gland. These two assays
are widely used to assess oncogenic
transformation, and PTNP12’s behavior
in these assays establishes it as a candi-
date tumor suppressor gene in mammary
epithelial cells. Importantly, the ability of
PTPN12 to block growth in these assays
depends on its tyrosine phosphatase
activity.
Sun and colleagues then characterize
the signaling events altered by disruption
of PTPN12. The phosphorylation of spe-
cific tyrosines on both the EGFR and
HER2 receptor tyrosine kinases increases,
as does the activity of the downstream
ERK/RSK (extracellular signal-regulated
kinase/ribosomal S6 kinase) pathway.
Together, these results indicate that
PTPN12 acts as a growth suppressor by
antagonizing key receptor tyrosine kinase
pathways.
Further, an analysis of PTPN12 gene
sequences reveals a series of point muta-
tions found only in triple-negative breast
cancer cells. Using in vitro functional
tests, Sun and colleagues confirm that
these mutations represent loss-of-func-
tion alleles. Additionally, 20% of all breast
cancers contain deletions encompassing
PTPN12, although other genes within the
deleted region may also be involved in
tumorigenesis. Perhaps most strikingly,
Sun and colleagues find that 60% of
triple-negative breast cancer cells are
histologically negative for PTPN12 in
a panel of 185 breast cancers, whereas
only 9% of HER2-positive cancers are
PTPN12 negative.nc.Sun and colleagues also note that the
PTPN12mRNAcontains threebindingsites
for miR-124, a microRNA repressed by the
tumor suppressor REST (RE1-silencing
transcription factor). The expression of
REST correlates with that of PTPN12,
which is consistent with miR-124 sup-
pressing PTPN12. In addition, overex-
pressing miR-124 promotes anchorage-
independent growth, as was observed
when PTPN12 was disrupted. The miR-
124 locus is amplified in 20% of breast
cancers, suggesting yet another mecha-
nism by which PTPN12 expression may
be lost in cancer. Together, these findings
strongly suggest that PTPN12 loss plays
a role in triple-negative breast cancers.
Moreover, the near mutual exclusivity of
HER2 overexpression and loss of PTPN12
suggests that disrupting PTPN12 repre-
sents an alternate route for activating
survival and proliferation pathways known
to drive cancer development.
Another intriguing finding by Sun and
colleagues is that a common single-
nucleotide polymorphism in the PTPN12
locus (Thr573Ala) represents a loss-of-
function variant. Although the correlation
of this polymorphism with breast cancer
falls below a strict threshold of statistical
significance (p = 0.2), the trend hints that
this variant may predispose an individual
to breast cancer. Indeed, a previous study
sequenced this polymorphic locus in 19
breast cancer cell lines (Streit et al.,
2006), with the loss-of-function allele
occurring more frequently in triple-nega-
tive breast cancer cell lines (4 out of 9)
than in other types of breast cancer (2
out of 9). Interestingly, this previous study
also found that the alanine substitution,
Figure 1. Triple-Negative Breast Cancer Cell Lines Are Enriched
with Tyrosine Phosphorylation Sites
‘‘Triple-negative’’ breast cancers, which do not express the three major
molecular signatures of breast cancer cells (estrogen receptor, progesterone
receptor, and HER2), are heterogeneous and difficult to treat. Sun et al. (2011)
now find that the activity of the protein tyrosine phosphatase PTPN12 is lost in
many of these cancers. Here a Wilcoxon rank sum test was used to identify
tyrosine sites preferentially phosphorylated in triple-negative breast cancer
cell lines versus other types of breast cancer cells (all sites shown are signif-
icant at the p < 0.05 level and are ranked from top to bottom in order of
increasing p value). Asterisks indicate sites that may also be phosphorylated
on closely related proteins. Data provided by Ting-lei Gu of Cell Signaling
Technology, and the breast cancer dataset is downloadable from Phospho-
SitePlus at http://www.phosphosite.org/downloads/breastcancerdataset.gz.whichresidesoutside thecata-
lytic domain, enhanced phos-
phatase activity in vitro. Given
that Sun et al. found loss of
tumor suppressor function in
cultured cell transformation
assays, these results raise the
possibility that the alanine
substitution alters PTPN12
localization or its access to
substrates inside the cell.
Unfortunately, despite the
prevalence of PTPN12 loss in
triple-negative breast cancer
cells, there is currently no fea-
sible way to directly restore
the function of this phospha-
tase therapeutically. More-
over, although PTPN12 ap-
pears to regulate the EGFR/
HER2 pathway, inhibitors of
EGFR and HER2 have failed
to show clinical efficacy for
triple-negative breast can-
cers, even though many of
these breast cancers display
high levels of EGFR. There-
fore, reversing the effects of
PTPN12 loss may require inhi-
bition of multiple tyrosine
kinases. This prompted Sun
andcolleagues to identify addi-
tional targets of PTPN12 using
a bimolecular fluorescence
complementation assay.
These experiments pinpoint
the platelet-derived growth
factor receptor-b (PDGFR-b)
as another tyrosine kinase that
interactswith PTPN12. Indeed,
inhibiting both EGFR/HER2
and PDGFR-b with two inhibi-
tors, lapatinib and sunitinib,
slows the growth of xeno-
grafted triple-negative breast
cancer tumors.
Importantly, the centralconcept advanced by Sun and colleagues
isnot thatPDGFR-b is a key target in triple-
negative breast cancer—indeed, datasets
from Oncomine (http://oncomine.org)
indicate that PDGF-a/b are not preferen-
tially expressed in triple-negative breast
cancer—but rather that the treatment of
this obstinate cancer may require combi-
natorial inhibition of multiple tyrosine
kinases. In support of this idea, we note
that many sites of tyrosine phosphoryla-tion are enriched in triple-negative breast
cancer cell lines (Figure 1), based on
mass spectrometry analysis of immunoaf-
finity-purified phosphopeptides (Ting-
lei Gu, Cell Signaling Technology;
http://www.phosphosite.org/downloads/
breastcancerdataset.gz). Many of these
sites are located on receptor tyrosine
kinases (e.g., EGFR, MET, Axl, and
EphAs), Src family kinases (SFKs), and
proteins involved in cell adhesion and tightCell 144, March 4junctions (e.g., caveolin, des-
moplakin, cingulin, and clau-
din-1). Together, these data
are consistent both with Sun
and colleagues’ conclusion
that loss of PTPN12 in triple-
negative breast cancer cells
stimulates a wide range of
signaling programs and with
other studies linking PTPN12
to the regulation of cell adhe-
sion and motility (Angers-
Loustau et al., 1999; Garton
and Tonks, 1999).
The promiscuity of tyrosine
kinase signaling networks
has also been observed in
lungcancer, inwhich signaling
behaves as a highly intercon-
nected web of substrates
that collapses dramatically
when key ‘‘hub’’ tyrosine
kinases are inhibited (Guo
et al., 2008; Rikova et al.,
2007). These webs appear to
be highly flexible, resulting in
cells with variable sensitivity
to tyrosine kinase inhibitors,
depending on the cell’s profile
of kinases and phosphatase
levels. Given that a number of
tyrosine kinase inhibitors are
currently approved for treat-
ment of other cancers, each
of which targets three or
more different tyrosine
kinases, it will be of great
interest to determine whether
combinations of these drugs
are effective against triple-
negative breast cancer, and
whether PTPN12 status can
predict sensitivity.
Although the work of Sun
and colleagues opens a new
window on a poorly under-
stood and aggressive malig-nancy, it also underscores the inherent
difficulties in targeting complex cancers
like triple-negative breast cancers. The
signaling changes that accompany the
loss of PTPN12 or overexpression are
modest, in the range of 2- to 3-fold. This
suggests that PTPN12 exerts its potent
phenotypic effects not through a single
main effector but rather by many small
changes distributed throughout a signal-
ing network., 2011 ª2011 Elsevier Inc. 639
Lastly, it is important to note that
a sizable fraction of the general population
(2.5%) harbors single-nucleotide polymor-
phisms that inactivate the tumor sup-
pressoractivityofPTPN12,but themajority
of these individuals do not develop cancer.
Therefore, loss of PTPN12 alone is not
sufficient to drive tumor formation. Inter-
estingly, the effect of PTPN12 appears
confined to theERK/RSKpathway,without
affecting the important PI3K/Akt pathway.
This observation suggests that PTPN12
loss cooperates with mutations in other
pathways, including thePI3K/Aktpathway,
which is hyperactivated in nearly 50% of640 Cell 144, March 4, 2011 ª2011 Elsevier Ibreast cancers. These considerations
together lead us to conclude that, although
PTPN12 may be an important piece of the
triple-negative breast cancer puzzle, it is
still a member of an even larger constella-
tion of alterations that together drive this
recalcitrant malignancy.REFERENCES
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The target of rapamycin complex 2 (TORC2) is a key regulator of cell growth. Zinzalla et al. (2011)
now provide evidence that TORC2 is activated by direct association with the ribosome, which
may ensure that TORC2 activity is calibrated to match the cell’s intrinsic growth capacity.TOR is an atypical serine/threonine
protein kinase conserved from yeast to
mammals that forms two distinct physical
and functional complexes termed TORC1
and TORC2 (Figure 1) (Wullschleger et al.,
2006). TORC1, a rapamycin-sensitive
complex, regulates translation, autoph-
agy, cell growth, and cell size. In contrast,
TORC2 is not directly inhibited by rapa-
mycin and controls cell survival and
morphology. The frequent dysregulation
of mammalian TOR (mTOR) signaling
observed in human cancer is thought to
contribute to tumorigenesis (Zoncu
et al., 2011). Extensive studies have re-
vealed the molecular mechanisms of
mTORC1 regulation in response to
signals, such as growth factors, cellular
energy status, nutrient availability, and
stress. Although compelling evidencehas placed TORC2 downstream of phos-
phatidylinositol 3-kinase (PI3K) and
upstream of the serine/threonine kinase
AKT, it has been unknown how TORC2
is regulated (Wullschleger et al., 2006).
Using a combination of elegant genetic
screening and sophisticated biochemical
studies, Zinzalla et al. (2011) significantly
advance our understanding of TOR
biology by identifying the ribosome as
a missing link between PI3K and
mTORC2 (Figure 1).
In yeast, TORC2 phosphorylates and
activates YPK2, the ortholog of mamma-
lian kinase SGK1, a known substrate of
mammalian TORC2. Loss of TORC2 func-
tion is lethal in yeast; however, overex-
pression of a constitutively active YPK2
suppresses the lethality caused by
a loss-of-function TORC2 mutation(Kamada et al., 2005). Zinzalla et al. de-
signed a clever reverse suppressor
screen in search of yeast mutants that
require the expression of constitutively
active YPK2 for survival. This strategy
was aimed at uncovering mutations in
TORC2 upstream activators. Perhaps
not surprisingly, many mutations isolated
were found in genes encoding compo-
nents of TORC2. Interestingly, the only
non-TORC2 component isolated was
NIP7, which encodes a protein involved
in the maturation of rRNA and ribosome
biogenesis. Survival of NIP7 mutant yeast
requires overexpression of the constitu-
tively active YPK2. Many scientists would
abstain from studying ribosomal proteins
because their inactivation may disrupt
protein translation and lead to pleiotropic
effects. Undeterred, Hall and colleagues
